MedinCell’s partner Teva announces successful launch of UZEDY™
August 2, 2023
August 2, 2023
MedinCell has received the last tranche of €10m from the European Investment Bank (EIB) loan
July 31, 2023
July 31, 2023
MedinCell announces the availability of its 2022-23 Universal Registration Document including the Annual Financial Report
July 31, 2023
July 31, 2023
MedinCell announces its full year financial results April 2022 – March 2023
June 26, 2023
June 26, 2023
MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023
June 5, 2023
June 5, 2023
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
May 22, 2023
MedinCell announces the successful pricing of its Global Offering and raises €25 million
May 12, 2023
May 12, 2023
MedinCell launches a Global Offering for approximately 25 million euros
May 11, 2023
May 11, 2023
MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
May 4, 2023
May 4, 2023
First FDA approval and US commercial launch, MedinCell enters new era
